Clinical Trial Update: A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and immunogenicity of three heterologous two-dose regimens of Ebola prophylactic vaccines in healthy adults has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Prophylactic vaccines for Ebola (three heterologous two-dose regimens)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Ebola Viral Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-02-08